Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891560 | 0.76 | TAAR1 (0.44) | TAAR1CXCR2HTR1ADRD2HTR7 | |
| SCHEMBL16545200 | 0.76 | TAAR1 (0.44) | TAAR1CXCR2HTR1ADRD2HTR7 | |
| SCHEMBL6647596 | 0.76 | TAAR1 (0.47) | TAAR1CXCR2HTR1ADRD2HTR7 | |
| SCHEMBL12891564 | 0.76 | TAAR1 (0.44) | TAAR1CXCR2HTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL11539056 | 0.74 | TAAR1 (0.46) | TAAR1HTR1ADRD2HTR7NOS3 | |
| SCHEMBL13344500 | 0.72 | TAAR1 (0.39) | TAAR1HTR1ADRD2HTR7 | |
| SCHEMBL16543102 | 0.72 | TAAR1 (0.41) | TAAR1CXCR2HTR1ADRD2HTR7 | |
| SCHEMBL2040174 | 0.72 | TAAR1 (0.41) | TAAR1CXCR2HTR1ADRD2HTR7 | |
| SCHEMBL16545303 | 0.72 | TAAR1 (0.44) | TAAR1HTR1ADRD2HTR7 | |
| SCHEMBL18723617 | 0.72 | TAAR1 (0.41) | TAAR1CXCR2HTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635839-B1 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2010-09-01 | — | — | EP | disclosed |
| EP-1828197-B1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | EP | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| EP-1828197-A1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE | Solvay Pharmaceuticals GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063615-A1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1635839-A2 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | Solvay Pharmaceuticals B.V. (NL) | 2006-03-22 | — | — | EP | disclosed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| WO-2005032527-A2 | BENZO (4, 5) THIENO (2, 3-D) PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-04-14 | — | — | WO | disclosed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | TAAR1 2447/4885CXCR2 4031/4885HTR1A 1792/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | TAAR1 2447/4885CXCR2 4031/4885HTR1A 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.